# A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)

> **NCT06730061** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ipsen** · enrollment: 18 (actual)

## Conditions studied

- Primary Biliary Cholangitis

## Interventions

- **DRUG:** Elafibranor

## Key facts

- **NCT ID:** NCT06730061
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-16
- **Primary completion:** 2026-12-17
- **Final completion:** 2032-04-08
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06730061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06730061, "A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06730061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*